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ARTICLE
RNAi-based glyconanoparticles trigger apoptotic
pathways for in vitro and in vivo enhanced cancer-cell
killing
João Conde a,†, Furong Tian b,†, Yulan Hernandez c, Chenchen Bao d, Pedro V. Baptista e,
Daxiang Cui d, Tobias Stoeger b* and Jesus M de la Fuente c,d,f*
Gold glyconanoparticles (GlycoNPs) are full of promises in areas like biomedicine,
biotechnology and material science due to their amazing physical, chemical and biological
properties. Here, siRNA GlycoNPs (AuNP@PEG@Glucose@siRNA) in comparison to
PEGylated GlycoNPs (AuNP@PEG@Glucose) were applied in vitro to a luciferaseCMT/167 adenocarcinoma cancer cell line and in vivo via intratracheal instillation
directly into the lung of B6 albino mice grafted with luciferase -CMT/167 adenocarcinoma
cells. siRNA GlycoNPs but not PEGylated GlycoNPs induced the expression of proapoptotic proteins such as Fas/CD95 and caspases 3 and 9 in CMT/167 adenocarcinoma
cells in a dose dependent manner, independent from the inflammatory response,
evaluated by bronchoalveolar lavage cell counting. Moreover, in vivo pulmonary
delivered siRNA GlycoNPs were capable of targeting c-Myc gene expression (a crucial
regulator of cell proliferation and apoptosis) via in vivo RNAi in tumour tissue, leading to
a ~80% reduction in tumour size without inflammation associated.

Introduction
Carbohydrates are, together with nucleic acids and proteins,
important molecules for life. Although individual carbohydrate
interactions are relatively weak, nature utilized multivalent
interactions between these cell surface ligands and their
respective biological receptors to modulate biological events
such as the ones related to cell adhesion, normal tissue growth
and repair, viral/bacterial infection, signal transduction,
trapping of leukocytes, and gene transfer. So the decoding of
carbohydrate interactions opens up the possibility to employ
physiologically inert gold nanoclusters in diagnostics and/or
therapy.1 Among them, gold glyconanoparticles (GlycoNPs)
have drawn more attention owing to their well-defined
features
as
water-soluble
carbohydrate-functionalized
nanoclusters with a promising potential for chemical
glycobiology,
biomedicine,
diagnostics
and
clinical
applications. In the last 10 years, de la Fuente and co-workers
have extensively reported a pioneered integrated
glyconanotechnology strategy based on the use of
nanoparticles to study and evaluate carbohydrate–
carbohydrate, carbohydrate–protein interactions 2-6 and used
as potential tools in anti-adhesive therapy 7, for cell-cell
adhesion studies 8 and for the prevention of pathogen
invasion.9
Small carbohydrates such as glucose can be attached to gold
nanoparticles (AuNPs) and may be useful mainly in sensitive
colorimetric assays.10 However, to the best of our knowledge
the use of siRNA GlycoNPs for the regulation of important

genes of the apoptotic pathways has never been described so
far.
Herein, a novel structure of multifunctional RNAi-based
GlycoNPs functionalized with glucose, poly(ethylene glycol)
(PEG), a biotin linked fluorophore and cMyc targeting siRNA
were designed to trigger apoptosis and gene silencing
pathways (see Figure 1). Via a chemical approach, the
functional properties and moieties of this kind of
multifunctional nanostructure can be easily tuned and
quantified as recently reported by our group.11,12 In fact, we
have provided evidence of in vitro and in vivo efficient RNAi via
the synthesis of a library of novel multifunctional AuNPs,
tested in three biological systems of increasing complexity: in
vitro cultured human cells (HeLa cells), in vivo freshwater polyp
(Hydra vulgaris), and in vivo mice models (B6 albino mice).11,13
In view of the great number of studies concerning glucotoxicity
attributed to the inability of cells to reduce glucose uptake
when exposed to chronic hyperglycemia, we designed novel
siRNA GlycoNPs that predispose gene expression to apoptosis
via enhancement of cell death receptors. In fact, it is known
that high levels of glucose induces apoptosis via upregulation
of cell death receptors – Fas – providing a link between type 1
and type 2 diabetes.14,15 Hyperglycemia is the central initiating
factor for all types of diabetic microvascular disease. Studies in
endothelial cell cultures clearly show glucose toxicity by
delaying replication, disturbing cell cycle, increasing DNA
damage and accelerating cell death.16,17
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Fi
gure 1. (A) Multifunctional siRNA Glyconanoparticles (siRNA GlycoNPs) trigger apoptotic pathways (B) with expression of cell
death receptors (Fas) and caspases. The death domain-containing receptor Fas can sense an external signal and activate the
apoptosis pathway through the Fas-related death domain. This pathway is mediated by the activation of caspase-8, followed by
direct cleavage of downstream effector caspases. The apoptosis pathway can also be initiated cytoplasmatic, through activation of
intracellular changes resulting in the release of proapoptotic factors from the mitochondria. The release of these factors leads to the
activation of caspase-9, and ultimately results in the activation of effector caspases (e.g. caspase 3) and consequently to cell death
by apoptosis. (C) The siRNA glycoNPs have also the capacity to trigger gene silencing via activation of the RNA interference
pathway, by double-stranded RNA (i.e. siRNA), promoting nucleolytic degradation of the target mRNA and/or translational
suppression.

Maedler et al. also reported that increased glucose
concentration by itself induces apoptosis in human pancreatic
β-cells via the upregulation of Fas receptors, which can interact
with the constitutively expressed FasL (Fas ligand) on
neighbouring β-cells. Fas-FasL interaction leads to cleavage of
procaspase-8 to caspase-8, which promotes caspase-3
activation.14 The stimulation of death receptors such as Fas
(APO-1/CD95) and creation of DISC (death-inducing signalling
complex) are commonly referred as the starting point in the
extrinsic apoptosis execution phase; whereas caspase-9
activation is a downstream marker for mitochondrial
membrane permeabilisation, in the intrinsic apoptotic
pathway.18 Both pathways converge on the same terminal
outcome, which is initiated by the cleavage of caspase-3 and

results in DNA fragmentation, degradation of cytoskeletal and
nuclear proteins, formation of apoptotic bodies, expression of
ligands for phagocytic cell receptors and finally clearance by
phagocytic cells.
Herein, the in vitro and in vivo activation of apoptotic and gene
silencing pathways via RNAi GlycoNPs will be dissected and the
clinical outcome in terms of lung cancer progression
evaluated.

Results and discussion
Glyconanoparticles synthesis and characterization
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Multifunctional gold glyconanoparticles were prepared by reduction
of sodium tetracholoroaurate(III) hydrate with sodium citrate as
described by Turkevich and Frens 19,20, and stabilized with
polyethyleneglycol (PEG) and subsequent conjugation with
glucose, biotin and siRNA. Briefly, the obtained AuNPs, with
an average diameter of 14 nm, were subsequently
functionalized with two types of thiolated poly(ethylene glycol)
(PEG) – a commercial carboxylated PEG (HS-EG(8)-(CH2)2COOH) and another one synthesized in our lab with an azide
group at the end (HS-(CH2)3-CONH-EG(6)-(CH2)2-N3) - by
exchange of the citrate groups,. For the subsequent attachment
of thiolated siRNA using the covalent approach previously
described 11, the AuNPs were functionalized with a 40% degree
of coverage of the surface using 50% of each PEG chain.
Once obtained stable and biocompatible PEGylated AuNPs we
functionalized them with amine-modified biotin and glucose
through an EDC coupling reaction forming amide bonds with
the carboxylic groups exposed on the surface. The covalent
conjugation of the biotin was evaluated by the crosslinking
induced by the effective attachment of streptavidin to up to four
biotin molecules and also determined by indirect quantification
by the Bradford assay. Concerning the attachment of glucose,
the change of the net charge and the aggregation of the AuNPs
effectively functionalized in the presence of the lectin
Concanavalin A 21 were used to confirm the conjugation, again
via the occurrence of crosslinking induced due to the multiinteraction between glucose and Con A. Lastly, GlycoNPs were
functionalized with thiolated anti cMyc siRNA through direct
attach of the thiol group to the gold core of the AuNP by
establishing strong pseudo-covalent bonds Au-S (for further
details see Supplementary Information)

Triggering apoptotic pathways via glyconanoparticles
The functionalized nanoparticles were administered in vitro to
a luciferase-CMT/167 adenocarcinoma cancer cell line and in
vivo via instillation directly into the lung of cancer mice (B6
albino
mice,
induced
with
luciferase-CMT/167
adenocarcinoma cells). 48 hours upon treatment with
increasing concentrations (10, 100 and 200 µg/mL) of
PEGylated GlycoNPs (AuNP@PEG@Glucose) and siRNA
GlycoNPs (AuNP@PEG@Glucose@siRNA) cells were assessed
for the expression of proapoptotic genes such as Fas/CD95 and
caspases-3 and -9, as well as the siRNA target c-Myc gene, that
also triggers apoptosis in association with tumour suppressors
such as ARF and p53.22
Representative confocal images of LA-4 adenocarcinomaloaded cells show that siRNA GlycoNPs accomplish high cellular
uptake (3-fold) and trigger apoptosis by enhancing the
expression of Fas death receptor, as detected by a significant
increase (2-fold) of Fas/CD95 fluorescence (Figure 2A).
Glucose-surface functionalization has also been developed for
siRNA GlycoNPs as a metabolic transporter to enhance the
uptake of the therapeutic nanoparticles by cancer cells. In fact,
tumour cells display a high rate of glucose uptake and
glycolysis, since cell proliferation requires increased uptake of
nutrients (e.g. glucose and glutamine). Cancer cells exhibit a
high rate of glycolysis even in the presence of oxygen (aerobic
glycolysis). The major function of aerobic glycolysis is to
maintain high levels of glycolytic intermediates to support
anabolic reactions in cells. This explains increased glucose
metabolism in proliferating cells.18 In addition to cell
proliferation, increased glucose uptake may also be associated
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with mitochondria damage in cancer cells, or an adaptation to
hypoxia environments within tumours or to mitochondria
shutdown by cancer genes (eg. c-Myc) involved in the cell's
apoptosis program.24 In fact, high glucose levels proved to be
pro-apoptotic, increasing the sensitivity to apoptosis via Fas
activation.14
Our results suggest that siRNA GlycoNPs activate apoptotic
pathways by regulating cell death receptors and effective
caspases, and the effect is dose dependent. Increasing
concentrations (10, 100 and 200 µg/mL) of siRNA GlycoNPs
show enhancement in Fas expression in a dose dependent
manner, as it can be seen by increase of Fas/CD95
fluorescence (see Figure 2B) in a 1.5-fold from 10 to 100
µg/mL and in a 3-fold from 100 to 200 µg/mL of NPs.
In order to corroborate these data and evaluate siRNA
GlycoNPs’ involvement in the activation of crucial proapoptotic
proteins, expression of Fas, caspase-3 and caspase-9 was
assessed
by
Western
blot
in
luciferase-CMT/167
adenocarcinoma cancer cell line. The expression of Fas,
activated/cleaved caspase-3 and caspase-9 proteins was
significantly higher (5 fold) for siRNA GlycoNPs at 10, 100 and
200 µg/mL compared to PEGylated GlycoNPs (Figure 3A).
The expression of Fas and caspases-3 from cell treated with 10
µg/mL of siRNA GlycoNPs indicates the strong activation of
both intrinsic and extrinsic apoptotic pathways. Enhanced
activation of caspase-9 by siRNA GlycoNPs can especially be
observed at 200 µg/mL (see Figure 2), which in turn may
induce the activation of procaspase-3, which leads to the
apoptosome formation.25 Once formed, the apoptosome can
then recruit and activate the inactive pro-caspase-9, which can
activate effector caspases and trigger a cascade of events
leading to apoptosis. Finally, after the activation of caspase-9,
the effector caspase-3 is activated and marks the endpoint of
apoptosis.25

Figure 2. Gold siRNA glyconanoparticles trigger apoptotic
pathways via expression of the Fas cell death receptor. (A)
Immunostaining
of
Fas/CD95
in
luciferase-CMT/167

ARTICLE

Nanoscale

adenocarcinoma cells treated with 200 µg/mL of PEGylated
glycoNPs and siRNA GlycoNPs for 48 hours. Cells stained for
DAPI (nuclei) in blue, actin (phalloidin) in green, Fas/CD95
stained in red and NPs (conjugated streptavidin with Cy7Allophycocyanin bound with biotin) in white (Scale bars, 20
μm). (B) Immunostaining of Fas/CD95 in luciferase-CMT/167
adenocarcinoma cells treated with 10, 100 and 200 µg/mL of
siRNA GlycoNPs. Cells stained for Fas/CD95 stained in red and
NPs (conjugated streptavidin with Cy7-Allophycocyanin bound
with biotin) in green (Scale bars, 20 μm). The results shown are
representative for at least three independent experiments.

This finding further supports the notion that siRNA GlycoNPs
promote apoptosis within the LA-4 adenocarcinoma cancer cell
line when exposed for 48 hours at a concentration of 100 and
200 µg/ml (Figure 3A,C). PEGylated GlycoNPs showed no
changes in expression of the assessed cell death receptor or
caspases (Figure 3A,C).
RNAi-based GlycoNPs were also functionalized with a siRNA to
mediate silencing of c-Myc gene expression. c-Myc is widely
known as a crucial regulator of cell proliferation in normal and
neoplastic cells, and recent reports strongly support a dual
function model for c-Myc as a co-ordinate activator of cell
proliferation and apoptosis.28 Several studies provide
evidences that c-Myc function is closely related to apoptosis
and that the induction or inhibition of apoptosis by this protein
may depend on the level of expression or cell lineages used. 2830 To assess whether anti-cMyc siRNA GlycoNPs attenuate MYC
protein synthesis, its expression was also evaluated by western
blot in luciferase-CMT/167 adenocarcinoma cancer cell line
(Figure 3B,C) after exposure to PEGylated GlycoNPs and siRNA
GlycoNPs. Western blot results clearly show that c-Myc
donwregulation (14-fold) is attained with only 10 µg/mL of
siRNA GlycoNPs (Figure 3B,C). PEGylated GlycoNPs show no
silencing effect for all NPs concentration (Figure 3B,C).

Figure 3. Activation of apoptotic pathway via siRNA GlycoNPs.
Fas, Caspase 3, Caspase 9 (A) and c-Myc expression (B) in
Western blot after LA-4 adenocarcinoma cancer cells treated
with increasing concentrations (0.1, 1, 10, 100 and 200 µg/mL)
of PEGylated GlycoNPs and siRNA GlycoNPs. (C) Comparative
graph with the expression of Fas, and activated Caspases 3 and
9 and c-Myc after LA-4 adenocarcinoma cancer cells treated
with PEGylated GlycoNPs and siRNA GlycoNPs. The results
shown are representative for at least three independent
experiments.

In vivo RNAi triggering via siRNA glyconanoparticles
For in vivo evaluation of GlycoNPs treatment on c-Myc
expression in a mouse lung tumour model, 200 µg/mL of
PEGylated GlycoNPs and siRNA GlycoNPs were administered to
mice
previously
induced
with
luciferase-CMT/167
adenocarcinoma cells. Four weeks after orthotropic lung
cancer induction mice were treated by instillation of 0.3 pmol
AuNP (at weeks 12, 13, 14 and 15), respectively, in 50 μl
pyrogene-free distilled water, followed by 100 μl of air. Figure
4A shows Hematoxylin and Eosin staining (H&E) and
immunolocalisation of c-Myc expression in mice lung tissues
for Sham, PEGylated GlycoNPs and siRNA GlycoNPs groups.
PEGylated GlycoNPs treated group demonstrates a cancer lung
tissue characterized by hypercellularity and thickened alveolar
septa. Cancer cell have spread throughout the lung tissue, and
large areas of deformed lung structures can be observed
(Figure 4A). Severe interstitial inflammatory cell infiltration is
noted in the PEGylated GlycoNPs treated group, with
predominance of perivascular and peribronchiolar edemas
(Figure 4A arrows). In the siRNA GlycoNPs-treated group in
contrast a significant decrease in the incidence and severity of
tumour foci in lung can be observed, revealing the potency of
siRNA GlycoNPs in reducing the tumour mass in the lung
cancer mouse model. Only few, scattered cancer cells can get

Nanoscale
localized with recovered alveolar lung tissue. Concerning
confocal images of lung tissue, Figure 4B shows high
expression of MYC protein in cytoplasm of tumour cells after
exposure to PEGylated GlycoNPs. Whereas, Figure 4C illustrate
tumour cells treated with siRNA GlycoNPs and shows
downregulation of local MYC expression (6-fold), probably
leading tumour cells to apoptosis, and consequently inhibiting
cell proliferation. Moreover, cancer cells in lung tissue
accumulate more siRNA GlycoNPs (2-fold) (Figure 4C) than
PEGylated GlycoNPs (Figure 4B). Xing and co-workers also
reported that glucose and antisense oligodeoxynucleotidescapped AuNPs showed significantly increased cellular uptake
compared to neutral nanoparticles in breast cancer 30 and
prostate cancer cells.31
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inflammatory response (Figure 5) upon treatment with
PEGylated GlycoNPs and siRNA GlycoNPs in cancer mice during
1, 3 and 14 days. Figure 5A shows representative microscope
images of BAL cells at day 1 and 14 for 200 µg/mL of PEGylated
GlycoNPs and siRNA GlycoNPs. Figure 5B shows evaluation of
the number of macrophages, lymphocytes and neutrophils in
cancer mice during 1, 3 and 14 days after PEGylated GlycoNPs
and siRNA GlycoNPs instillation. No multinucleated
macrophages, indicators of a foreign body response are found
at any condition. As expected13, Sham treated group (healthy
mice without lung cancer induction of luciferase-CMT/167
adenocarcinoma cells) reveals intact and normal alveolar
macrophages (Figure 5A). Inflammatory cells infiltration is
noted by increasing numbers of neutrophils in the siRNA
GlycoNPs (200 µg/mL) treated groups on days 1 and 14 (Figure
5A). PEGylated and siRNA GlycoNPs show the same pattern
and number of macrophages as well as neutrophils and
lymphocytes (Figure 5B). The increased number of neutrophils
with 200 µg/mL of PEGylated and siRNA GlycoNPs on day 1
indicates a moderate acute and over time rapidly declining
inflammatory response, resulting in baseline levels (sham) and
thus negligible neutrophil numbers at day 3 and 14 after
treatment (Figure 5B). No significant changes have been
observed for BAL lymphocyte numbers over the period of
investigation, pointing to the generally described innate, acute
inflammatory response to pulmonary deposited materials 32,33
No significant changes in the number of macrophages and
neutrophils between PEGylated GlycoNPs and siRNA GlycoNPs
are observed (Figure 5B).

Figure 4. RNAi triggering in mice. (A) Hematoxylin and eosin
(H&E) stains of Sham (healthy mice without lung cancer
induction of luciferase-CMT/167 adenocarcinoma cells),
PEGylated GlycoNPs and siRNA GlycoNPs treated groups in
lung tissue with induction of LA-4 adenocarcinoma cells.
Severe interstitial inflammatory cell infiltration is noted, with
predominance of perivascular and peribronchiolar edemas
(arrows) in PEGylated GlycoNPs only. Immunohistochemical
images of lung tissue of PEGylated GlycoNPs (B) and siRNA
GlycoNPs (C) treated groups. Cells in lung tissue stained for
actin in green and MYC stained in red (Scale bars, 100 μm).

Inflammatory response and in vivo glyconanoparticles
biodistribution in mice
The inflammatory response of the assembled glyconanoconjugates was evaluated by bronchoalveolar lavage
(BAL) cell analysis. At steady state conditions, the most
abundant cells retrieved in BAL fluid are the resident alveolar
macrophages that line the alveolar space, (about 98% of BAL
cells), and under inflammatory conditions infiltrating
leukocytes
such
as
lymphocytes
and
neutrophils.
Consequently, evaluation of the number of BAL macrophages,
lymphocytes and neutrophils was used to characterize the

Figure 5. Inflammatory response in bronchoalveolar lavage
(BAL) cells in mice during 1, 3 and 14 days of exposure to gold
GlycoNPs. (A) Representative microscope images of BAL cells
(scale bars, 20 μm) at days 1 and 14 for 200 µg/mL of
PEGylated GlycoNPs and siRNA GlycoNPs. Black arrows
indicate neutrophils. (B) Evaluation of the number of
macrophages, lymphocytes and neutrophils was used to detect
inflammatory response in the lungs during 1, 3 and 14 days
after PEGylated GlycoNPs and siRNA GlycoNPs instillation.
Sham groups correspond to healthy mice without lung cancer
induction and any nanoparticle treatment. Error bars indicate
± s.d, of n=6 mice.
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In order to analyse tumour size, nanoparticle uptake and
biodistribution in the whole body mice but predominantly in
lung tumour tissue, tomography bioluminescence imaging was
carried out in the mouse cancer model (B6 albino female mice
injected with luciferase-CMT/167 adenocarcinoma cells)
treated with 200 µg/mL of PEGylated GlycoNPs and siRNA
GlycoNPs (Figure 6). Representative whole body images of the
individual mice from each treated group (n = 8 animals) shown
at fixed photon flux scale illustrates the luciferase activity
(Figure 6A). Detection of epi-fluorescence (Figure 6B) further
allowed localization of nanoparticle conjugated to streptavidin
with Cy7-Allophycocyanin (Cy7APC, BD Pharmingen™) with an
excitation wavelength of at 642 nm. Figures 6C and 6D shows
excised organs to evaluate lung tumour size via the
luminescence of luciferase and Figures 6E and 6F shows
nanoparticle distribution in mice organs via the measurement
of epi-fluorescence of nanoparticles conjugated to streptavidin
with Cy7-Allophycocyanin (Exc = 642 nm).

Nanoscale
size via the luminescence of luciferase in mice treated with
PEGylated AuNPs (C) and gold GlycoNPs (D). Nanoparticle
distribution indifferent organs treated with PEGylated
GlycoNPs (E) and siRNA GlycoNPs (F), via the measurement of
epi-fluorescence of nanoparticles conjugated to streptavidin
with Cy7-Allophycocyanin.

The tomography images clearly depict that siRNA GlycoNPs
archive an increased targeting toward lung cancer cells when
compared to PEGylated GlycoNPs treatment, which shows no
signal-accumulation in the respective lung tissue, for the same
scale of epi-fluorescence. Once the lung is characterized by
high expression of c-Myc, siRNA anti-cMyc targeting GlycoNPs
seem to accumulate in the tissue more effectively and for a
longer period of time than observed for PEGylated GlycoNPs
only. Moreover, treatment of the murine lung cancer model
with GlycoNPs leads to successful tumour size reduction
(~80%) as depicted by the decrease in reporter luminescence
signal (Figure 6A,C), when compared to the PEGylated
GlycoNPs.

Experimental
Synthesis of PEGylated and siRNA GlycoNPs
Full description of synthesis and characterization methods of
PEGylated GlycoNPs and siRNA GlycoNPs can be found in
Supplementary Information.

Immunostaining of luciferase-CMT/167
adenocarcinoma cells
Cells were fixed with -20°C methanol for 10 min and with -20°C
acetone for min on cover slips. The cover slips were washed
twice in PBS, and then blocked with PBS containing 0.1% BSA
for 10 min at room temperature followed by draining. The cellside-up of glass slide was incubated with anti-rabbit Fas (Santa
Cruz Biotechnology) in PBS containing 1% BSA for 60 min, and
was washed three times in PBS. The samples were incubated
with Alexa 546 anti-rabbit or FITC 488 anti-rabbit as the
secondary antibody and phalloidin (Invitrogen), at the
recommended dilution, in PBS containing 1% BSA, for 30 min,
and then was washed for three times in PBS. After DAPI
staining, one drop of aqueous mounting medium was added
on the cover slip and inverted carefully on a glass slide. The
images were acquired in a Zeiss confocal microscope and the
fluorescent density per cell was analysed by ImageJ.
Figure 6. GlycoNPs uptake, whole body biodistribution and
tumour size assessment in mice. Tomography imaging of B6
albino female mice injected with luciferase-CMT/167
adenocarcinoma cells (n = 8 animals per treated group) treated
with 200 µg/mL of PEGylated GlycoNPs and siRNA GlycoNPs.
Representative imaging of individual mice from each
treatment group (n = 8 animals) is shown, with the same scale
of photon flux indicating luciferase activity (A) and epifluorescence (B) indicating nanoparticles conjugated to
streptavidin
with
Cy7-Allophycocyanin
(Cy7APC,
BD
Pharmingen™) with an excitation wavelength of at 642 nm.
(A,B) Luminescence and epi-fluorescence images of lung
cancer mice treated with 200 µg/mL of PEGylated GlycoNPs
and siRNA GlycoNPs. Excised organs to evaluate lung tumour

Western blot of Fas/CD95, caspase 3 and 9 expression
Protein extract was boiled in sample buffer for 3 min and
loaded onto 12% SDS-polyacrylamide gels. Details of the
Western immunoblotting procedure have been described
elsewhere.34 The antibodies used in this experiment were as
follows: anti-rabbit Fas (Santa Cruz Biotechnology, 1:500
dilution), anti-rabbit Caspase3 (cleaved) (Invitrogen, 1:500
dilution), and anti-rabbit polyclonal Caspase9 (cleaved)
(Abcam, 1:1000 dilution), anti-rabbit IgG horseradish
peroxidase (Amersham-Pharmacia Biotech, 50000:1 dilution).
The blot was visualized with an ECL kit (Amersham-Pharmacia
Biotech).
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In vivo targeting of PEGylated glycoNP and siRNA
GlycoNPs
Prior to glycoNP instillation, B6 albino mice (B6N-Tyrc/BrdCrCrl,
Charles River, France, induced with luciferase-CMT/167
adenocarcinoma cells) were anesthetized by intraperitoneal
injection of a mixture of Medetomidin (0.5 mg/kg body mass),
Midazolam (5.0 mg/kg body mass) and Fentanyl (0.05 mg/kg
body mass). The animals were then intubated by a nonsurgical
technique. Using a cannula inserted 10 mm into the trachea, a
suspension containing 1×105 cancer cells or 200 µg/mL of
PEGylated GlycoNPs and siRNA GlycoNPs, in 50 μl pyrogenefree distilled water was instilled, followed by 100 μl air. After
instillation animals were antagonized by subcutaneous injection
of a mixture of Atipamezol (2.5 mg/kg body mass), Flumazenil
(0.5 mg/kg body mass) and Naloxon (1.2 mg/kg body mass) for
antagonization and to control awakening of the mice. Animal
experiments were carried out according to the German law of
protection of animal life and were approved by an external
review committee for laboratory animal care (animal approval
number: 55.2-1-54-2532-20-11). After 72 hours mice lungs
were dissected and prepared for Hematoxylin and Eosin
staining (H&E) and for immunolocalisation by a standard
immunohistochemical procedure, to verify c-Myc expression
and the distribution of NPs by tissue sections.

Molecular analyses of MYC expression in mice
The lung cancer tissues (from B6 albino mice induced with
luciferase-CMT/167 adenocarcinoma cells) were embedded
and sliced into 3 m section. A standard Hematoxylin and
Eosin (H&E) staining was employed for cancer cells
morphology observation. For immunolocalisation, standard
immunohistochemical staining methods were employed: the
tissue slide was incubated with anti-mouse c-Myc and antirabbit caspase-3, (1:1000) in PBS containing 1% BSA for 60
min, and was washed three times in Tris-buffered saline (TBS).
The slide was incubated with 560 nm anti mouse and FITC antirabbit as the secondary antibody, at the recommended
dilution, in TBS containing 1% BSA, for 30 min, and then was
washed for three times in PBS. The slides were mounted with
50 µl of mounting medium. The images were acquired by a
Zeiss confocal microscopy and the fluorescent density per cell
analysed by ImageJ.
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linear Hygromycin resistance marker (Clonetech). A stable
clone (CMT/167-luc) expressing high levels of firefly luciferase,
constitutively driven by the SV40 promoter and enhancer, was
instilled into female C57BL/6 albino mice. Prior to instillation,
mice were anesthetized by intraperitoneal injection of a
mixture of Medetomidin (0.5 mg/kg body mass), Midazolam
(5.0 mg/kg body mass) and Fentanyl (0.05 mg/kg body mass).
The animals were then intubated by a nonsurgical technique.
Using a cannula inserted 10 mm into the trachea, a suspension
containing 1×105 CMT/167-luc cells in 50 μl pyrogene-free
distilled water was instilled, followed by 100 μl of air, at week
8. Four weeks after orthotropic lung cancer induction mice
were treated by instillation of 0.3 pmol AuNP (at weeks 12, 13,
14 and 15), respectively, in 50 μl pyrogene-free distilled water,
followed by 100 μl of air. After instillation animals were
antagonized by subcutaneous injection of a mixture of
Atipamezol (2.5 mg/kg body mass), Flumazenil (0.5 mg/kg
body mass) and Naloxon (1.2 mg/kg body mass). Luciferase
expression was monitored applying the IVIS® imaging system
(Lumina, PerkinElmer) from mice bearing tumours from
luciferase-CMT/167 cells (n = 8 animals per treated group).

Conclusions
Several studies were published in the last years reporting that
some engineered gold nanoparticles induce apoptosis in cells
via caspase pathways. Herein, we present for the first time a
new and smart RNAi-based gold glyconanoparticle system
capable of inducing apoptosis via hyperactivation of cell death
receptors and caspase pathways.
In summary, we
demonstrate that siRNA GlycoNPs have remarkable potential
to trigger apoptosis via the enhancement of cell death
receptors and activation of caspases. Moreover, our results
confirm that sham, PEGylated GlycoNPs and siRNA GlycoNPs
treated groups’ causes the same inflammatory response,
proving that siRNA GlycoNPs trigger apoptotic pathways via
expression of cell death receptors and effective caspases in a
specific way, independent from the inflammatory response.
Consequently, the switch on of the apoptotic pathways is not
caused by any toxic and/or adverse side effects of the
exposure to the NPs in mice. Most importantly, pulmonary
delivered of siRNA GlycoNPs leads to a ~80% reduction in
tumour size via in vivo RNAi in tumour tissue by targeting cMyc gene expression.

Preparation of BAL cells/fluid for evaluation of
inflammatory response
BAL (bronchoalveolar lavage cells) ﬂuid was obtained by
injecting 4 times and recovering of two 0.5 mL aliquots of PBS
via a tracheal cannula. Cells recovered with the lavage fluid
(lymphocytes and neutrophils accompanying the predominant
population of alveolar macrophages) were determined utilizing
light microscopic cell differentiation, counting 200 cells per
cytospin preparation. Details of the bronchoalveolar lavage
procedure were described elsewhere.35 Mice were exposed to
200 µg/mL of PEGylated GlycoNPs or siRNA GlycoNPs.

In vivo bioluminescence imaging
Stable clones of CMT64/61 cells, originally derived from a
spontaneous lung adenocarcinoma of a C57Bl/ICRF mouse 32
were generated by transfection with pGL3-Control vector
(Promega GmbH), and co-transfection for selection with a
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